|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status... |
|